Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 8/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 10/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858579 | 1.00 | PLA2G7 (0.40) | PLA2G7DPP4DPP8NTRK1 | |
| SCHEMBL13858578 | 1.00 | PLA2G7 (0.40) | PLA2G7DPP4DPP8NTRK1 | |
| SCHEMBL13858580 | 1.00 | PLA2G7 (0.40) | PLA2G7DPP4DPP8NTRK1 | |
| SCHEMBL13858573 | 0.86 | NTRK1 (0.46) | NTRK1 | |
| SCHEMBL13858437 | 0.86 | NTRK1 (0.46) | NTRK1 | |
| SCHEMBL18662308 | 0.86 | NTRK1 (0.46) | NTRK1 | |
| SCHEMBL20331669 | 0.86 | NTRK1 (0.46) | NTRK1 | |
| Hydrochloric Acid SCHEMBL13858516 | 0.84 | NTRK1 (0.45) | NTRK1 | |
| SCHEMBL15730051 | 0.82 | CYP2D6 (0.46) | DPP4NTRK1 | |
| SCHEMBL13974925 | 0.82 | CYP2D6 (0.46) | DPP4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851080-B2 | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds | ARRAY BIOPHARMA INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3409670-B1 | N-PYRROLIDINYL, N'-PYRAZOLYL- UREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180179182-A1 | METHODS OF TREATMENT USING PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-9896435-B2 | N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9878997-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9790178-B2 | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790178-B2 | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9562055-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160297758-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2014078372-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | PLA2G7 4486/4885DPP4 3452/4885DPP8 3103/4885 |
| US-20180179182-A1 | METHODS OF TREATMENT USING PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS | RNMT, MTAP, GMPS | PLA2G7 2847/4885DPP4 2860/4885DPP8 2330/4885 |
| US-20160297758-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, UACA, TYMP | PLA2G7 4085/4885DPP4 2427/4885DPP8 2276/4885 |
| US-10851080-B2 | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds | RNMT, MTAP, GMPS | PLA2G7 2847/4885DPP4 2860/4885DPP8 2330/4885 |
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | PLA2G7 4486/4885DPP4 3452/4885DPP8 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.